PDCD1 and non-small cell lung carcinoma: Patients with advanced metastatic cutaneous melanoma or NSCLC who were scheduled to be treated with systemic anti–PD-1–based immunotherapy or chemoimmunotherapy were enrolled in a prospective research registry [Hillman Cancer Center (HCC) 20-019] that included the administration of a validated, web-based, semi-quantitative Diet History Questionnaire III (DHQ III) FFQ that quantified self-reported dietary intake (Supplementary Fig. S1A; Supplementary Appendix S1 and S2).